X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2410) 2410
oncology (2244) 2244
index medicus (1951) 1951
chemotherapy (1633) 1633
female (1482) 1482
cancer (1185) 1185
antineoplastic combined chemotherapy protocols - therapeutic use (1096) 1096
aged (1014) 1014
middle aged (992) 992
male (859) 859
adult (813) 813
treatment outcome (781) 781
care and treatment (693) 693
paclitaxel (650) 650
breast cancer (630) 630
antineoplastic agents - therapeutic use (598) 598
docetaxel (598) 598
breast neoplasms - drug therapy (592) 592
phase-ii trial (581) 581
metastasis (529) 529
phase-iii trial (520) 520
pharmacology & pharmacy (518) 518
medicine & public health (508) 508
lung neoplasms - drug therapy (476) 476
antineoplastic combined chemotherapy protocols - adverse effects (469) 469
research (454) 454
cisplatin (453) 453
drug therapy (435) 435
carcinoma, non-small-cell lung - drug therapy (429) 429
open-label (410) 410
hematology, oncology and palliative medicine (407) 407
clinical trials (396) 396
trastuzumab (390) 390
trial (388) 388
disease-free survival (382) 382
therapy (380) 380
neoplasm staging (372) 372
survival (367) 367
deoxycytidine - analogs & derivatives (356) 356
aged, 80 and over (352) 352
paclitaxel - administration & dosage (350) 350
breast neoplasms - pathology (347) 347
gemcitabine (338) 338
randomized-trial (336) 336
1st-line treatment (333) 333
plus (310) 310
health aspects (308) 308
combination (305) 305
bevacizumab (293) 293
neoplasm metastasis (293) 293
survival rate (293) 293
antineoplastic agents (292) 292
prognosis (286) 286
antimitotic agents (280) 280
taxoids - administration & dosage (280) 280
cancer therapies (278) 278
drug administration schedule (275) 275
deoxycytidine - administration & dosage (273) 273
adjuvant chemotherapy (271) 271
carboplatin (265) 265
clinical trials as topic (264) 264
analysis (262) 262
plus cisplatin (261) 261
survival analysis (259) 259
antineoplastic combined chemotherapy protocols - administration & dosage (255) 255
cancer research (253) 253
double-blind (244) 244
lung neoplasms - pathology (234) 234
cooperative-oncology-group (231) 231
capecitabine (229) 229
phase-ii (226) 226
cell lung-cancer (224) 224
animals (221) 221
cisplatin - administration & dosage (221) 221
carcinoma (217) 217
pharmacology/toxicology (216) 216
stomach neoplasms - drug therapy (213) 213
radiotherapy (209) 209
supportive care (208) 208
carcinoma, non-small-cell lung - pathology (207) 207
chemotherapy, adjuvant (204) 204
oncology, experimental (203) 203
randomized controlled trials as topic (202) 202
tumors (200) 200
antibodies, monoclonal, humanized (199) 199
growth-factor receptor (198) 198
patients (195) 195
antineoplastic agents - adverse effects (194) 194
lung cancer, non-small cell (194) 194
antineoplastic agents - administration & dosage (191) 191
fluorouracil (188) 188
surgery (186) 186
neoadjuvant therapy (184) 184
multicenter (183) 183
1st-line therapy (181) 181
receptor, erbb-2 - metabolism (181) 181
review (181) 181
endothelial growth-factor (180) 180
retrospective studies (177) 177
lung cancer (176) 176
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 09/2015, Volume 12, Issue 9, pp. 508 - U25
Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly paclitaxel considered equivalent to... 
TRIAL | THERAPY | ONCOLOGY | NAB-PACLITAXEL | IXABEPILONE | METASTATIC BREAST-CANCER | PHASE-II | DOCETAXEL | PLUS BEVACIZUMAB | CHEMOTHERAPY | Usage | Paclitaxel | Breast cancer | Genetic aspects | Research | Drug therapy | Health aspects
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2012, Volume 23, Issue 4, pp. 1016 - 1022
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 14, pp. 2995 - 3002
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. e646 - e652
Background Favorable progression‐free survival (PFS) and overall survival (OS) results were previously reported on a phase II trial of patients with human... 
Human epidermal growth receptor 2 positive | Breast cancer | Metastatic | Pertuzumab | Trastuzumab | SURVIVAL | DOCETAXEL | PLUS TRASTUZUMAB | TRIAL | AMPLIFICATION | ONCOLOGY | HER2 | PROGRESSION
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2010, Volume 123, Issue 1, pp. 149 - 157
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 15, pp. 2592 - 2601
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 18, pp. 3831 - 3838
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 20, pp. 2593 - 2599
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2018, Volume 169, Issue 2, pp. 333 - 340
The purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are... 
Neoadjuvant therapy | HER-2-positive | Medicine & Public Health | Pertuzumab | Pathological complete response | Oncology | Breast cancer | Trastuzumab | MULTICENTER | OPEN-LABEL | COMBINATION | PLUS TRASTUZUMAB | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | LAPATINIB | THERAPY | ONCOLOGY | CLINICAL-TRIALS | CONCURRENT | Cyclophosphamide - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Breast Neoplasms - epidemiology | Antibodies, Monoclonal, Humanized - adverse effects | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Epirubicin - adverse effects | Anthracyclines | Cyclophosphamide | Analysis | Adjuvant treatment | Clinical trials | Product development | Health aspects | Cancer
Journal Article
Journal Article